Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Docetaxel and 177-Lutetium-PSMA-I&T in mCRPC
NCT07316686Phase 1Recruiting
- Sponsor
- Instituto do Câncer do Estado de São Paulo
- Start
- Jun 2026
- Primary completion
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of docetaxel and lutetium Lu 177 PSMA I&T in prostate cancer (PCa) (3 arms), sponsored by Instituto do Câncer do Estado de São Paulo. Primary endpoint: Recommended Phase II Dose at 3 weeks. Started Jun 2026; status: recruiting.
02
Drugs
docetaxellutetium Lu 177 PSMA I&T
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT07316686.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07316686.